Notizie | bioMérieux Italia

First-Half 2020 Results

02 Settembre, 2020

Launch of BIOFIRE^® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 Luglio, 2020

Second-Quarter 2020 Business Performance Preannouncement

15 Luglio, 2020

BIOFIRE^® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 Luglio, 2020

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS^®

27 Maggio, 2020

BIOFIRE^® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains FDA Emergency Use Authorization

04 Maggio, 2020

COVID-19: comunicazione di A.Mérieux, CEO di bioMérieux

31 Marzo, 2020

First-Quarter 2020 Business Review

24 Marzo, 2020

bioMérieux receives Emergency Use Authorization for BIOFIRE^® COVID-19 test

24 Marzo, 2020

First of 3 diagnostic tests for SARS-CoV-2 coronavirus available from bioMérieux

11 Marzo, 2020

Pioneering diagnostics

bioMérieux Corporate | bioMérieux Industry | bioMérieux Diagnostics

bioMérieux Italia Spa | Sede Legale Via di Campigliano, 58 Loc.Ponte a Ema

50012 Bagno a Ripoli (FI) Italia | Capitale Sociale € 9.000.000 i.v. Socio Unico

n.REA FI 443558 | C.F. 07146020586 | P.IVA 01696821006